Education
About Us
Working with TipRanks
Follow Us
Oxford Biomedica (otc) (OXBDF)
OTHER OTC:OXBDF
OXBDF Stock Chart & Stats
$7.90
-$0.05(-0.85%)
At close: 4:00 PM EST
$7.90
-$0.05(-0.85%)
Day’s Range― - ―
52-Week Range$3.15 - $10.60
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.47K
Market Cap
$1.19B
Enterprise Value$387.11M
Total Cash (Recent Filing)$53.88M
Total Debt (Recent Filing)$105.42M
Price to Earnings (P/E)―
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding120,752,960
10 Day Avg. Volume8,533
30 Day Avg. Volume3,474
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)7.62
Price to Sales (P/S)3.37
P/FCF Ratio-7.48
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda-360.10
Forecast
1Y Price Target
$9.03Price Target Upside14.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Order BookThe company's contracted order book reached approximately £186m in 2024, representing over a 30% increase year-over-year.
Revenue GrowthOXB delivered revenues of £128.8m, in line with its January trading update and previous guidance, representing 44% growth YoY.
Bears Say
Macroeconomic HeadwindsThere is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.
Oxford BioMedica News
OXBDF FAQ
What was Oxford Biomedica (otc)’s price range in the past 12 months?
Oxford Biomedica (otc) lowest stock price was $3.15 and its highest was $10.60 in the past 12 months.
What is Oxford Biomedica (otc)’s market cap?
Oxford Biomedica (otc)’s market cap is $1.19B.
When is Oxford Biomedica (otc)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oxford Biomedica (otc)’s earnings last quarter?
Currently, no data Available
Is Oxford Biomedica (otc) overvalued?
According to Wall Street analysts Oxford Biomedica (otc)’s price is currently Undervalued.
Does Oxford Biomedica (otc) pay dividends?
Oxford Biomedica (otc) does not currently pay dividends.
What is Oxford Biomedica (otc)’s EPS estimate?
Oxford Biomedica (otc)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford Biomedica (otc) have?
Oxford Biomedica (otc) has 120,752,960 shares outstanding.
What happened to Oxford Biomedica (otc)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford Biomedica (otc)?
Currently, no hedge funds are holding shares in OXBDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oxford BioMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.03 (14.25% Upside)
$9.03 (14.25% Upside)
Blogger Sentiment
Bullish
OXBDF Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $306.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.37%
12-Months-Change
Fundamentals
Return on Equity
-74.64%
Trailing 12-Months
Asset Growth
-4.27%
Trailing 12-Months
Company Description
Oxford Biomedica (otc)
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
OXBDF Company Deck
OXBDF Earnings Call
Q2 2025
0:00 / 0:00
OXBDF Stock 12 Month Forecast
Average Price Target
$9.03
▲(14.25% Upside)
Technical Analysis
Avacta Group plc
―
PureTech Health
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Arecor Therapeutics PLC
―
Ownership Overview
Options Prices
Currently, No data available
---